U.S.

With sleep apnea drug under review, Apnimed prices $192M IPO

Fri, 31 Jul 2026 12:00:00 -0400

Eyeing a potential drug launch early next year, Apnimed Inc. has entered the public market via an upsized IPO, pricing 12 million shares at $16 apiece for gross proceeds of $192 million. Another $24 million could come if underwriters exercise their overallotment option for an additional 1.5 million shares.

AB2 Bio triggers $30M milestone as Nippon Shinyaku takes up US option

Fri, 31 Jul 2026 12:00:00 -0400

Nippon Shinyaku Co. Ltd. has taken up its option on U.S. rights to AB2 Bio Ltd.’s interleukin-18 neutralizing drug, tadekinig alfa, triggering a payment of $30 million and opening the way to a further $650 million in development and commercialization milestones for the Swiss biotech. The rights relate to the use of tadekinig in the treatment of primary pediatric IL-18-driven hyperinflammation, an ultra-rare inherited disorder that if left untreated can lead to multi-organ failure and death.

Mimedx to buy Sanara for $350M to move beyond wound care

Fri, 31 Jul 2026 12:00:00 -0400

Mimedx Group Inc. agreed to buy Sanara Medtech Inc. in a cash and stock deal for a total enterprise value of approximately $350 million as it looks to expand its surgical footprint. The move is part of Mimedx strategy to transform the company after its wound care business was hit on the back of CMS changes to reimbursement for skin substitutes.

Low coffers, failed endometrial cancer trial: Karyopharm down 72%

Fri, 31 Jul 2026 12:00:00 -0400

Quickly running out of cash, Karyopharm Therapeutics Inc. found itself in a precarious situation July 30 when top-line phase III results showed Xpovio (selinexor) failed to meet the progression-free survival primary endpoint in endometrial cancer. The Newton, Mass.-based company last reported cash of $91.2 million as of the end of the first quarter (Q1), enough to fund operations through the latter part of Q3. Karyopharm, founded in 2008, is now exploring financings and strategic alternatives.

US CDC, ASPR nominees get HELPing hand toward Senate confirmation

Thu, 30 Jul 2026 12:00:00 -0400

Erica Schwartz is one step away from becoming the next director of the U.S. CDC. The Senate Health, Education, Labor and Pensions (HELP) Committee voted 13-10 July 30 to favorably report her nomination to the Senate floor for confirmation. The committee also favorably reported the nomination of Sean Kaufman, on a party line vote of 12-11, to be the assistant secretary for preparedness and response (ASPR) at the Department of Health and Human Services.

J&J Sails away, Legend left at altar; $2.58B buyout ahead?

Thu, 30 Jul 2026 12:00:00 -0400

The hot in vivo CAR T therapy space bubbled with news again as Johnson & Johnson (J&J) apparently forsook partner Legend Biotech Corp. and tapped Sail Biomedicines Inc. for a collaboration that will help advance the lead immune-mediated disease program as well as the broader platform technology, in a tie-up that brings incentives to expand the application of Sail's platform across more targets later.

Replimune’s RP-1 for melanoma wins over FDA adcom

Thu, 30 Jul 2026 12:00:00 -0400

Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma refractory to PD-1 therapy cleared a major hurdle when the U.S. FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10-3 that the efficacy results from the Ignyte phase II study are evaluable and clinically meaningful.

Boston Sci cuts guidance: have its star products lost their shine?

Wed, 29 Jul 2026 12:00:00 -0400

Boston Scientific Corp. cut its guidance for the year on the back of increasing pressure on its Watchman and electrophysiology businesses, two units which have performed strongly in recent years.

Atea’s hep C pill looks solid in phase III head-to-head HCV study

Wed, 29 Jul 2026 12:00:00 -0400

News of the first-ever successful head-to-head phase III study testing an oral antiviral therapy for hepatitis C virus (HCV) might not have had much impact on Atea Pharmaceuticals Inc.’s share price, but analysts remained optimistic for the future of the once-daily fixed-dose combination of bemnifosbuvir and ruzasvir.

Resin peace, Capricor? SAP spat, weak data foil DMD adcom bid

Wed, 29 Jul 2026 12:00:00 -0400

The saga of Capricor Therapeutics Inc.’s allogeneic cell therapy deramiocel for cardiomyopathy in Duchenne muscular dystrophy (DMD) added another bleak chapter as the U.S. FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted on the question of whether the available data provide “substantial evidence” that the drug works. Balloting turned out 9 no, 3 yes.

Fauci’s silence may put him in contempt of Congress

Wed, 29 Jul 2026 12:00:00 -0400

After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci, the now retired head of the NIH’s National Institute of Allergy and Infectious Diseases, faces a committee vote next week on a resolution citing him for contempt.

Kolon Tissuegene shares fall as TG-C misses knee OA endpoints